Trial reportBreast cancer research and treatment2026
Role of individualized intervention(s) on quality of life and adherence to adjuvant endocrine therapy in premenopausal women with early-stage breast cancer: MyCHOICE study.
Trial report in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundPremenopausal women receiving combination endocrine therapy often experience substantial declines in quality of life (QOL), cognitive functioning, and treatment adherence. The MyChoice study evaluated whether individualized behavioral and complementary interventions could help maintain or improve QOL and treatment adherence in women with early-stage hormone receptor-positive breast cancer undergoing aromatase inhibitor- or tamoxifen-based therapy with ovarian suppression.
methodsIn this prospective multicenter phase II study, premenopausal women with newly diagnosed hormone receptor-positive breast cancer were enrolled prior to initiation of combination endocrine therapy. Tailored supportive interventions, including structured exercise programs, restorative yoga, acupuncture, and massage therapy, were offered, and women could choose one or more interventions either alone or in combination. QOL and cognitive function were assessed at baseline, 3 months, and every 6 months for up to 3 years using FACT-B, FACT-ES, and FACT-Cognitive Function instruments. Adherence to endocrine therapy was assessed at each follow-up visit using physician-conducted patient interviews and pharmacy refill records. Longitudinal changes in QOL and their demographic and clinical predictors were analyzed using linear mixed-effects models.
resultsForty premenopausal women participated, with a median age of 43 years. Exercise was the most frequently selected intervention (61%), followed by massage therapy (44%), acupuncture (35%), and yoga (30%). Functional well-being improved significantly over time (1.65 points per year, p = 0.0005). Emotional well-being, social/family well-being, physical well-being, endocrine symptoms, and perceived cognitive abilities remained stable. Adherence to endocrine therapy was high at 92.5% over the follow-up period. In multivariable analyses, younger age (< 35 years) was associated with less favorable outcomes across several domains, including lower FACT-ES scores and lower physical well-being.
conclusionIndividualized, patient-selected supportive interventions may help maintain key aspects of quality of life and support adherence to endocrine therapy in premenopausal women with early-stage breast cancer. These findings support further evaluation in larger, controlled trials.
Indexed as
Identifiers
42360361What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.